Inspire Medical Systems is implementing a strategic shift called Project Horizon to stabilize its growth trajectory following significant coding and reimbursement disruptions for its Inspire V system. The company reported second-quarter revenue of $200.6 million, a 7.6% decrease, with an estimated $40 million adverse impact from coding and reimbursement challenges. Despite the headwinds, management raised its full-year 2026 revenue guidance to a range of $835 million to $875 million, citing improving trends in prior authorization submissions and favorable proposed 2027 facility reimbursement rates from CMS. Project Horizon is expected to create $30 million of annualized growth investment capacity through organizational streamlining and supply chain optimization, with pretax restructuring charges of $20 million to $25 million, approximately 90% of which will be recognized in the third quarter. The company also reported adjusted diluted earnings per share of $0.14 and a gross margin of 85.5%, driven by a higher sales mix of the Inspire V system.
Inspire Medical Systems IncRaises full-year revenue guidance and reports Q2 earnings despite restructuring charges.
ARKO Petroleum Corp.